ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

Authors

Laurie Helen Sehn

British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada

Laurie Helen Sehn , Brad S. Kahl , Matthew J. Matasar , Georg Lenz , Koji Izutsu , Weili Zhao , Lin Tao , Roser Calvo , Pier Luigi Zinzani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

First Author: Anas Younes

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

First Author: Laurie Helen Sehn

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

First Author: Herve Tilly

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.

First Author: Nathan Hale Fowler